Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
Nemaura Medical (NASDAQ: NMRD), a medical technology firm, announced that CEO Faz Chowdhury, Ph.D., will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nemaura Medical (NASDAQ: NMRD), a medical technology firm, announced that CEO Faz Chowdhury, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled virtually from September 13 – 15, 2021. The corporate presentation will be available starting September 13 at 7:00 AM ET. Investors can register for the conference on the official website. Nemaura specializes in non-invasive diagnostic devices, including sugarBEAT®, a CE-approved continuous glucose monitor, and proBEAT™, an AI-driven health service.
Details
News Market Reaction – NMRD
The recorded move for NMRD in the trading session of this news was +9.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Loughborough, England, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 – 15, 2021.
Dr. Chowdhury will deliver his corporate presentation, which will become available beginning on September 13 at 7:00 AM ET.
Investors can register here: www.hcwevents.com.
Mr. Chowdhury will also be available for one-on-one meetings throughout the conference.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.